DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

HUM·Humana Inc.

$.
-. (-.%)
High
$434.95
Open
$424.54
Market Cap
49.08B
52W High
$415.00
Low
$389.08
P. Close
$407.78
P/E
43.43
52W Low
$163.11
Fwd P/E
25.44
DailyIQ Est.
$332.21
Technical Score (1D)
82
BUY
News Sentiment
83
BULLISH
UnitedHealth Group’s Q2 earnings beat expectations and the company raised its full‑year guidance, signaling stronger future performance for the health‑insurance sector. The earnings lift lifts investor sentiment toward health‑insurance stocks, including Humana, which trades in a sector that has been sensitive to earnings surprises. Humana’s shares jumped after analysts highlighted upside potential in Medicare Advantage enrollment, but the company’s operating margins and earnings still lag behind expectations. The contrast between UnitedHealth’s guidance hike and Humana’s margin concerns suggests that the sector may be in a phase of re‑pricing, with investors weighing growth prospects against profitability. Over the next 1–10 trading days, the market will likely focus on how Humana’s Medicare Advantage enrollment data and margin guidance compare to UnitedHealth’s stronger outlook. A positive Medicare Advantage enrollment report could help Humana sustain its recent rally, while a margin downgrade could trigger a pullback. Traders should watch Humana’s upcoming Q3 earnings release for updated margin guidance and any commentary on Medicare Advantage performance. Additionally, regulatory developments that could affect health‑insurance margins, such as changes to Medicare Advantage reimbursement rates, will be a key catalyst for the sector. The interplay between UnitedHealth’s optimistic guidance and Humana’s margin concerns may also influence broader healthcare sector rotation in the near term. Finally, keep an eye on any shifts in the health‑insurance index that could signal a broader sector rebalancing.
Earnings Summary
Humana Inc. is a U.S.-based healthcare company that primarily offers medical and specialty insurance products through its Insurance and CenterWell segments, serving individuals, employer groups, and government programs such as Medicare and Medicaid, and differentiating itself with integrated pharmacy benefit management and home health solutions. In the healthcare plans sector, Humana competes on the basis of its Medicare Advantage strategy and cost‑control initiatives. In the most recent quarter, Q4 2025, the company posted a revenue of $32.64 billion, slightly down from the $32.65 billion reported in Q3 2025, but a sharp decline from the $32.39 billion in Q2 2025, while the prior quarter’s revenue rose modestly from $29.21 billion in Q4 2024 to $32.11 billion in Q1 2025; EPS swung from a negative $3.96 in Q4 2025 to a positive $10.31 in Q1 2026, reversing the negative trend seen in Q4 2025 and following a pattern of beating estimates in four of the last five quarters (Q1 2025, Q2 2025, Q3 2025, Q1 2026) but missing in Q4 2025. Historically, Humana’s revenue has trended upward year over year, with a notable acceleration in Q1 2026, while EPS has been volatile, reflecting the company’s ongoing transition to Medicare Advantage and the impact of cost‑control measures. Recent analyst upgrades—Raymond James, Truist, TD Cowen, Wells Fargo, and Mizuho—all raised price targets and cited Medicare Advantage growth and margin expansion as key drivers, underscoring market confidence in the company’s earnings trajectory. Investors should watch for the next earnings call to gauge guidance on Medicare Advantage enrollment, the effectiveness of cost‑control initiatives, and any regulatory updates that could affect reimbursement rates, as these factors will likely shape the company’s profitability outlook in the coming quarter.

EPS

EstBeatMiss
$-6.29$-1.24$3.81$8.86$13.91Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.97 - -
Q1'26$10.16$10.31+1.5%
Q4'25$10.57$-3.96-137.5%
Q3'25$2.83$3.24+14.6%
Q2'25$5.87$6.27+6.9%
Q1'25$10.07$11.58+15.0%

Revenue

EstBeatMiss
$30.8B$33.7B$36.6B$39.5B$42.4BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$41.0B - -
Q1'26$39.4B$39.6B+0.7%
Q4'25$35.5B$32.6B-8.1%
Q3'25 - $32.6B -
Q2'25 - $32.4B -
Q1'25 - $32.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

HUM Stock Snapshot

HUM is currently trading at $394.30, giving Humana Inc. a market cap of 49.08B and a P/E ratio of 43.4. Today's range spans $389.08–$434.95, with shares opening at $424.54 and moving down $13.48 (3.3%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 83/100.

Over the past year HUM has traded between $163.11 and $415.00 - the current price is +141.7% off the 52-week low and -5.0% from the high. 34 analysts cover the stock with a Hold consensus and a mean 12-month target of $330.08 (range $195.00–$502.00), implying downside of -16.3%.

Humana Inc. (HUM) is a large-cap in Healthcare with 49.08B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 82/100 (BUY). Sentiment: bullish at 83/100. Price: $394.30 (near 52-week highs). The current P/E ratio stands at 43.4. The 52-week range of $163.11–$415.00 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.

What makes HUM's BUY setup (82/100) particularly actionable at 49.08B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $394.30 (near 52-week highs in $163.11–$415.00), with sentiment running bullish at 83/100, the setup rewards conviction-sized positioning more than it does speculative small bets.